The Chinese University of Hong Kong

Macao, with over 400 years of history, serves as a cultural bridge between China and the West. The University of Macau (UM) focuses on international exchanges, particularly with Portuguese-speaking countries, contributing to the Greater Bay Area's development. UM collaborates with universities in Portugal, Mozambique, and Angola, fostering joint research and talent training. Macao's unique language and legal system connections with Portuguese-speaking countries enhance its role as a platform for economic and trade cooperation. UM aims to develop students into global talents, integrating into national and global development.

Taletrectinib, a next-gen ROS1 TKI, shows superior efficacy, CNS penetration, and safety in ROS1+ NSCLC, with TRUST-I trial data revealing 90.6% ORR in TKI-naive patients and 51.5% in crizotinib-pretreated. TRUST-II global trial supports consistent activity and safety, with pooled analysis confirming taletrectinib's benefit as a first-line option.

Hua Medicine announced SENSITIZE study results at CBIIC, showing dorzagliatin improves β-cell glucose sensitivity in IGT and restores GK activity in GCK-MODY, enhancing insulin secretion in T2D patients.

ALE.P02, an ADC targeting CLDN1, received FDA fast track designation for treating advanced CLDN1+ squamous cancers. It includes a tubulin inhibitor linked to an anti-CLDN1 antibody, designed to attack overexpressing CLDN1 tumors with less toxicity. ALE.P02's phase 1/2 trial is set to start in Q1 2025, with ALE.P03, another ADC using a topoisomerase I inhibitor, also in development.

The Greater Bay Area International Clinical Trial Institute (GBAICTI) opened in Hong Kong Park of Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone, marking a milestone in the 'one zone, two parks' development. The GBAICTI aims to leverage Hong Kong's international advantages to promote clinical trials and biomedical technology development, collaborating with Shenzhen's counterpart center to extend the research network and expedite clinical trials within the Greater Bay Area.

The FDA granted fast track designation to ALE.P02, an anti-CLDN1 ADC for CLDN1-positive squamous solid tumors. ALE.P02, featuring a tubulin inhibitor, aims to offer a less toxic treatment. A phase 1/2 trial is set to launch in Q1 2025. Alentis is also developing ALE.P03, an ADC with a topoisomerase I inhibitor.

The FDA granted fast track designation to ALE.P02, an anti-CLDN1 ADC for CLDN1-positive squamous solid tumors, potentially offering a less toxic treatment. ALE.P02, featuring a tubulin inhibitor, targets CLDN1 overexpressed in squamous cancers, with a phase 1/2 trial set to launch in Q1 2025. Alentis Therapeutics is also developing ALE.P03, an ADC with a topoisomerase I inhibitor.

FDA grants Fast Track designation to Alentis Therapeutics' ALE.P02, a first-in-class ADC targeting CLDN1 for advanced or metastatic CLDN1+ squamous cancers, irrespective of organ origin.

Chinese University of Hong Kong and ETH Zurich conducted world's first remote tele-endoscopy, performing a biopsy on a porcine model in Hong Kong from Zurich via a magnetic endoscope and robotic platform, facilitated by WebSocket protocol. The research highlighted potential for remote critical care and timely diagnosis/treatment of gastrointestinal cancer.